{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:27:00Z","timestamp":1777890420630,"version":"3.51.4"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The clinical management of refractory pituitary neuroendocrine tumors (PitNETs) remains a formidable challenge due to pervasive resistance to traditional therapies. Current therapeutic failures appear closely associated with lineage-specific immune heterogeneity and the unique \u201chypovascular-fibrotic\u201d physical barrier that hinders drug delivery. This review critically examines the biological determinants of therapeutic resistance in the tumor microenvironment (TME) to propose a comprehensive framework for precision immuno-oncology. We highlight how immune infiltration profiles and checkpoint expressions are strongly influenced by transcriptional lineages across PIT1-, TPIT-, and SF1-lineage tumors. We elucidate the \u201chypovascular-fibrotic\u201d barrier, where low microvessel density and dense collagen deposition restrict therapeutic penetration. We also evaluate advanced strategies, including spatial multi-omics for precise patient stratification and focused ultrasound (FUS) for enhanced drug delivery. In the end, we outline potential combinatorial strategies integrating vascular normalization and metabolic reprogramming to synergize with immune checkpoint inhibitors. This mechanism-driven paradigm shift from empirical treatment to precision immuno-oncology may provide critical insights and novel therapeutic strategies for intractable PitNETs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1796402","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:19Z","timestamp":1777613839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiayu","family":"Song","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liusu","family":"Ding","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulian","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Mao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13302","article-title":"The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors","volume":"35","author":"Casar-Borota","year":"2025","journal-title":"Brain Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1558988","article-title":"Editorial: Diagnosis and treatment of non-functioning pituitary tumors","volume":"16","author":"Sav","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf434","article-title":"Debate: Surgery as initial therapy for microprolactinoma","volume":"110","author":"Molitch","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61111973","article-title":"The PitNET puzzle: From zero to linking molecular behavior with neurosurgical aspects","volume":"61","author":"Kamel","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1227\/neu.0000000000003608","article-title":"Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of medical perioperative management for patients with functioning pituitary adenomas","volume":"97","author":"Turin","year":"2025","journal-title":"Neurosurgery"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae010","article-title":"Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors","volume":"7","author":"Mantziaris","year":"2025","journal-title":"Neuro-Oncol Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/thno.114257","article-title":"Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy","volume":"15","author":"Ijaz","year":"2025","journal-title":"Theranostics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003383","article-title":"Congress of Neurological Surgeons systematic review and evidence-based guidelines update for the role of emerging therapies in the management of patients with metastatic brain tumors","volume":"96","author":"Huntoon","year":"2025","journal-title":"Neurosurgery"},{"key":"B11","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-17-0796","article-title":"European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.012","article-title":"Cancer hallmarks intersect with neuroscience in the tumor microenvironment","volume":"41","author":"Hanahan","year":"2023","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217492","article-title":"Emerging neuroimmune mechanisms in cancer neuroscience","volume":"612","author":"Huang","year":"2025","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01017-z","article-title":"Targeting the peripheral neural-tumour microenvironment for cancer therapy","volume":"23","author":"Yaniv","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: Therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-023-01473-x","article-title":"Tumor-associated myeloid cells in cancer immunotherapy","volume":"16","author":"Cheng","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: An emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101605","article-title":"The microenvironment of pituitary tumors-biological and therapeutic implications","volume":"11","author":"Ilie","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216908","article-title":"Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors","volume":"592","author":"Guo","year":"2024","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.12.003","article-title":"The emergence of natural killer cells as a major target in cancer immunotherapy","volume":"40","author":"Souza-Fonseca-Guimaraes","year":"2019","journal-title":"Trends Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-024-01325-4","article-title":"Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors","volume":"16","author":"Lin","year":"2024","journal-title":"Genome Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04382-8","article-title":"Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): Increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset","volume":"163","author":"Luo","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cells14131019","article-title":"An old new friend: Folliculo-stellate cells in pituitary neuroendocrine tumors","volume":"14","author":"Nastase","year":"2025","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40478-025-01986-1","article-title":"Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance","volume":"13","author":"Peng","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156707","article-title":"Valproic acid promotes transcriptional activation of Drd2 by mediating histone acetylation to inhibit the mTOR-Pttg1 signaling axis and exerts anti-PitNETs activity","volume":"141","author":"Du","year":"2025","journal-title":"Phytomedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13313","article-title":"Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective","volume":"35","author":"Botelho","year":"2025","journal-title":"Brain Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70435","article-title":"Role of somatostatin receptor 2 (SSTR2) in pituitary adenomas","volume":"15","author":"Power","year":"2025","journal-title":"Clin Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02642-0","article-title":"Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: A systematic review and meta-analysis","volume":"48","author":"Costanza","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01314-8","article-title":"Structural insights into somatostatin receptor 5 bound with cyclic peptides","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11102-025-01537-w","article-title":"Genes of the \"regulation of lymphocyte activation\" pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors","volume":"28","author":"Chiloiro","year":"2025","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mce.2017.08.006","article-title":"Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease","volume":"463","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01029","article-title":"Antipsychotic drug trifluoperazine suppresses colorectal cancer by inducing G0\/G1 arrest and apoptosis","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1567-5769(01)00068-6","article-title":"Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis","volume":"1","author":"Saha","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189007","article-title":"The association between the neuroendocrine system and the tumor immune microenvironment: Emerging directions for cancer immunotherapy","volume":"1878","author":"Li","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02219-0","article-title":"Neuroscience of cancer: Unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-025-01748-5","article-title":"The neuro-immune axis in cancer: From mechanisms to therapeutic opportunities","volume":"18","author":"Zhang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B38","article-title":"Ultrastructural changes in the capillary bed of human pituitary tumors","volume":"67","author":"Schechter","year":"1972","journal-title":"Am J Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13245","article-title":"Parallel trajectories in the discovery of the SCN-OVLT and pituitary portal pathways: Legacies of Geoffrey Harris","volume":"35","author":"Silver","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1038\/s41467-021-25793-z","article-title":"Identification of the suprachiasmatic nucleus venous portal system in the mammalian brain","volume":"12","author":"Yao","year":"2021","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140019","article-title":"Hypothalamus as an endocrine organ","volume":"5","author":"Clarke","year":"2015","journal-title":"Compr Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13490","article-title":"Capillary connections between sensory circumventricular organs and adjacent parenchyma enable local volume transmission","volume":"37","author":"Yao","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.3.1159","article-title":"Angiogenesis in pituitary adenomas and the normal pituitary gland","volume":"85","author":"Turner","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cimb48010027","article-title":"Exploring the dynamic interaction between pituitary neuroendocrine tumors (Pit-NETs) cells and their angiogenic microenvironment by using the MIB1 labeling index, VEGF expression and digital image analysis","volume":"48","author":"Cozma","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3892\/etm.2021.10690","article-title":"Consistency of pituitary adenomas: Amounts of collagen types I and III and the predictive value of T2WI MRI","volume":"22","author":"Li","year":"2021","journal-title":"Exp Ther Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.20944\/preprints202106.0185.v1","article-title":"Consistency of pituitary adenoma: Prediction by pharmacokinetic dynamic contrast-enhanced MRI and comparison with histologic collagen content","volume":"13","author":"Kamimura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12022-025-09867-y","article-title":"Reticulin framework assessment in neoplastic endocrine pathology","volume":"36","author":"Mortara","year":"2025","journal-title":"Endocr Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2025.100408","article-title":"Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications","volume":"41","author":"Liu","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02126-5","article-title":"Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-\u03b3-induced tumour-associated fibroblasts remodelling","volume":"128","author":"Lyu","year":"2023","journal-title":"Br J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41467-025-60028-5","article-title":"Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression","volume":"16","author":"Su","year":"2025","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.07.024","article-title":"Role of TGF-\u03b21\/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma","volume":"1698","author":"Hu","year":"2018","journal-title":"Brain Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.brainresbull.2019.03.013","article-title":"miR-93-5p targets Smad7 to regulate the transforming growth factor-\u03b21\/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma","volume":"149","author":"Hu","year":"2019","journal-title":"Brain Res Bull"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00736-5","article-title":"Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-016-0140-9","article-title":"Alterations of collagen-producing cells in human pituitary adenomas","volume":"49","author":"Tofrizal","year":"2016","journal-title":"Med Mol Morphol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.37940","article-title":"Understanding the mechanical properties of pituitary adenomas for optimized surgery","volume":"113","author":"Gautam","year":"2025","journal-title":"J BioMed Mater Res A"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/thno.117691","article-title":"Tissue-type differences in focused ultrasound and microbubble-mediated drug delivery to the brain exist at vessel level","volume":"16","author":"De Maio","year":"2026","journal-title":"Theranostics"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114408","article-title":"Integrated focused ultrasound and electromagnetic actuation (FUEM) system for enhanced targeted drug delivery in brain cancer treatment","volume":"389","author":"Kee","year":"2026","journal-title":"J Control Release"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s531451","article-title":"Advances and challenges in nano-delivery systems for glioblastoma treatment: a comprehensive review","volume":"20","author":"Wang","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181450","article-title":"The pituitary immune environment and immunotherapy: from hypophysitis to pituitary neuroendocrine tumors","volume":"14","author":"Tateno","year":"2025","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184471","article-title":"PD-L1 expression in pituitary neuroendocrine tumors\/pituitary adenomas","volume":"15","author":"Cossu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108506","article-title":"Therapeutic targeting of the pituitary tumor microenvironment","volume":"250","author":"Ilie","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/erc-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1530\/eje-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111963","article-title":"Pituitary-related adverse events and onset patterns caused by immune checkpoint inhibitors: analysis using the Japanese adverse drug event report database","volume":"59","author":"Asano","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-025-03296-9","article-title":"Single-cell transcriptomics identify a novel macrophage population associated with bone invasion in pituitary neuroendocrine tumors","volume":"44","author":"Wu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"36873","DOI":"10.1038\/s41598-025-20826-9","article-title":"Anti PD-L1 immunotherapy alters macrophage phenotypes via EGR1 and HSP90AB1 supported by integrated methodologies","volume":"15","author":"Shou","year":"2025","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011057","article-title":"Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and antitumoral activity upon IL-10 or TGF\u03b2 stimulation","volume":"13","author":"Traxel","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.actbio.2025.10.018","article-title":"Tuning the polyethylene glycol-lipid anchor length of lipid nanoparticles to enhance brain-targeted siRNA delivery","volume":"207","author":"Tong","year":"2025","journal-title":"Acta Biomater"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1039\/d5nr02548f","article-title":"Crossing the blood-brain barrier: advances in dendrimer-based nanocarriers for central nervous system delivery","volume":"17","author":"Bharadwaj","year":"2025","journal-title":"Nanoscale"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98098","article-title":"Ultrasound flow imaging for assessing cerebrovascular changes following focused-ultrasound blood-brain barrier opening","volume":"15","author":"Bae","year":"2025","journal-title":"Theranostics"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2025.10.006","article-title":"A multifunctional theranostic ultrasound platform for remote magnetogenetics and expanded blood-brain barrier opening","volume":"18","author":"Batts","year":"2025","journal-title":"Brain Stimul"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115584","article-title":"Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication","volume":"44","author":"Guo","year":"2025","journal-title":"Cell Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13244-025-02125-z","article-title":"Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events","volume":"16","author":"Amseian","year":"2025","journal-title":"Insights Imaging"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030436","article-title":"Immunotherapy-related hypophysitis: a narrative review","volume":"17","author":"Di Stasi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf178","article-title":"Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumors","volume":"110","author":"Lin","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1614223","article-title":"Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.09.031","article-title":"Analysis of cyclooxygenase 2, programmed cell death ligand 1, and arginase 1 expression in human pituitary adenoma","volume":"144","author":"Zhao","year":"2020","journal-title":"World Neurosurg"},{"key":"B79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-025-02025-9","article-title":"Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors","volume":"13","author":"Martinez-Mendoza","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1629621","article-title":"The evolution and application of multi-omic analysis for pituitary neuroendocrine tumors","volume":"12","author":"Pugazenthi","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.14791\/btrt.2022.10.f-2696","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01673-2","article-title":"Lactate dehydrogenase B facilitates disulfidptosis and exhaustion of tumour-infiltrating CD8(+) T cells","volume":"27","author":"Wan","year":"2025","journal-title":"Nat Cell Biol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.1239","article-title":"Intratumoral heterogeneity and immunotherapy resistance: clinical implications","volume":"37","author":"Keenan","year":"2026","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12902-025-02039-3","article-title":"Classification of and risk factors for sodium imbalance developing after transsphenoidal surgery for pituitary neuroendocrine tumors","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812468","article-title":"Pseudocapsule-based resection for pituitary adenomas via the endoscopic endonasal approach","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05228-1","article-title":"Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience","volume":"175","author":"Brand","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003582","article-title":"Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiosurgery for patients with functioning pituitary adenomas","volume":"97","author":"Green","year":"2025","journal-title":"Neurosurgery"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613974","article-title":"Case report: abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11102-025-01556-7","article-title":"Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenoma","volume":"28","author":"Rajan","year":"2025","journal-title":"Pituitary"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00227-x","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859633","article-title":"Next-generation anti-angiogenic therapies as a future prospect for glioma immunotherapy; from bench to bedside","volume":"13","author":"Shamshiripour","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2025.102013","article-title":"Anatomy of the pituitary gland","volume":"39","author":"Sav","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B94","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/2159-8290.cd-22-0455","article-title":"Targeting microglial metabolic rewiring synergizes with immune-checkpoint blockade therapy for glioblastoma","volume":"13","author":"Ye","year":"2023","journal-title":"Cancer Discov"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.02.005","article-title":"Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma","volume":"11","author":"Lira","year":"2025","journal-title":"Trends Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41467-025-56821-x","article-title":"Splicing diversity enhances the molecular classification of pituitary neuroendocrine tumors","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012505","article-title":"Mapping the cancer vaccine landscape","volume":"13","author":"Hu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.09.032","article-title":"A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-\u03b1 secretion in vivo","volume":"34","author":"Zhang","year":"2025","journal-title":"Mol Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202510229","article-title":"A programmable nanovaccine platform based on M13 bacteriophage for personalized cancer vaccine and therapy","volume":"37","author":"Huang","year":"2025","journal-title":"Adv Mater"},{"key":"B101","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3892\/or.2025.8988","article-title":"Novel tetravalent bispecific antibody, PSMA\/TRAIL\u2013R2 REGULGENT\u2122, induces selective tumor cell apoptosis without hepatotoxicity","volume":"54","author":"Nakayama","year":"2025","journal-title":"Oncol Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01447-z","article-title":"Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy","volume":"10","author":"Liu","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B103","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12951-025-03696-1","article-title":"Biomimetic Cu(2-x)Se nanoplatforms for efficient glioblastoma treatment: overcoming the blood-brain barrier and boosting immunogenetic cell death","volume":"23","author":"Lin","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114225","article-title":"Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy","volume":"387","author":"Woodring","year":"2025","journal-title":"J Control Release"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649468","article-title":"Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.09.002","article-title":"Spatially resolving cancer: from cell states to therapy","volume":"12","author":"Pei","year":"2025","journal-title":"Trends Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101740","article-title":"The spatial multi-omics revolution in cancer therapy: precision redefined","volume":"5","author":"Du","year":"2024","journal-title":"Cell Rep Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae055","article-title":"Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis","volume":"190","author":"Zhang","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14883","article-title":"Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration","volume":"30","author":"Guevara-Salinas","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01949-x","article-title":"Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease","volume":"33","author":"\u00c1lvarez-Luqu\u00edn","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41419-021-03778-6","article-title":"DA-DRD5 signaling controls colitis by regulating colonic M1\/M2 macrophage polarization","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106963","article-title":"Dopamine D1 receptor agonist A-68930 ameliorates A\u03b2(1-42)-induced cognitive impairment and neuroinflammation in mice","volume":"88","author":"Cheng","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","article-title":"Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome","volume":"160","author":"Yan","year":"2015","journal-title":"Cell"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172826","article-title":"Dopamine attenuates lipopolysaccharide-induced expression of proinflammatory cytokines by inhibiting the nuclear translocation of NF-\u03baB p65 through the formation of dopamine quinone in microglia","volume":"866","author":"Yoshioka","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2009.10.015","article-title":"The immunoregulatory role of dopamine: an update","volume":"24","author":"Sarkar","year":"2010","journal-title":"Brain Behav Immun"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112458","article-title":"Dopamine, a co-regulatory component, bridges the central nervous system and the immune system","volume":"145","author":"Li","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01305-8","article-title":"Refractory lactotroph adenomas","volume":"26","author":"Urwyler","year":"2023","journal-title":"Pituitary"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1796402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:20Z","timestamp":1777613840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1796402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2026.1796402"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1796402","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1796402"}}